Table 1 Baseline patient characteristics (full analysis set)

From: Home blood pressure-lowering effect of esaxerenone vs trichlormethiazide for uncontrolled hypertension: a prespecified subanalysis of the EXCITE-HT randomized controlled study by age subgroup

Characteristics

<65 years

≥65 years

Esaxerenone n = 137

Trichlormethiazide n = 133

Esaxerenone n = 158

Trichlormethiazide n = 157

Sex, male

74 (54.0)

82 (61.7)

75 (47.5)

78 (49.7)

Age, years

54.9 ± 6.7

54.0 ± 7.9

74.2 ± 6.1

73.9 ± 6.1

Weight, kg

72.95 ± 14.76

73.16 ± 14.08

59.35 ± 10.97

61.10 ± 11.10

Body mass index, kg/m2

27.04 ± 4.92

26.86 ± 4.66

23.94 ± 3.07

24.41 ± 3.38

Morning home SBP, mmHg

137.9 ± 14.8

136.9 ± 12.5

142.0 ± 15.0

141.6 ± 13.3

Morning home DBP, mmHg

90.2 ± 9.7

90.1 ± 9.2

84.0 ± 8.7

83.6 ± 8.4

Bedtime home SBP, mmHg

133.7 ± 16.0

n = 133

134.0 ± 13.6

135.5 ± 15.7

n = 148

134.8 ± 14.4

n = 149

Bedtime home DBP, mmHg

84.6 ± 10.6

n = 133

85.4 ± 10.1

78.7 ± 9.5

n = 148

77.7 ± 10.2

n = 149

Office SBP, mmHg

141.2 ± 14.0

140.1 ± 15.3

146.1 ± 18.1

145.0 ± 14.7

Office DBP, mmHg

87.9 ± 10.7

88.3 ± 11.6

79.6 ± 11.0

79.3 ± 11.2

NT-proBNP, pg/mL

51.75 ± 99.88

n = 104

53.80 ± 166.14

n = 116

154.64 ± 397.27

n = 133

109.29 ± 124.43

n = 137

 <55

76 (73.1)

93 (80.2)

49 (36.8)

47 (34.3)

 55 to <125

21 (20.2)

17 (14.7)

42 (31.6)

55 (40.1)

 ≥125

7 (6.7)

6 (5.2)

42 (31.6)

35 (25.5)

UACR, mg/gCr

103.50 ± 583.89

96.87 ± 563.19

127.33 ± 374.21

105.15 ± 255.49

 <30

97 (70.8)

98 (73.7)

96 (60.8)

89 (56.7)

 30 to <300

35 (25.5)

28 (21.1)

48 (30.4)

55 (35.0)

 ≥300

5 (3.6)

7 (5.3)

14 (8.9)

13 (8.3)

Serum potassium, mEq/L

4.16 ± 0.36

n = 133

4.18 ± 0.32

n = 127

4.25 ± 0.34

n = 153

4.24 ± 0.32

n = 151

Uric acid, mg/dL

5.52 ± 1.38

5.66 ± 1.15

5.27 ± 1.14

5.19 ± 1.22

n = 156

eGFRcreat, mL/min/1.73 m2

76.60 ± 15.84

77.27 ± 15.61

n = 131

67.07 ± 14.28

67.82 ± 17.14

n = 156

Duration of hypertension, years

3.88 ± 4.26

n = 85

4.41 ± 4.13

n = 86

6.59 ± 5.40

n = 99

6.38 ± 5.57

n = 98

Complication

131 (95.6)

121 (91.0)

154 (97.5)

155 (98.7)

 T2DM

50 (36.5)

49 (36.8)

69 (43.7)

66 (42.0)

 Dyslipidemia

86 (62.8)

71 (53.4)

102 (64.6)

100 (63.7)

 Hyperuricemia

29 (21.2)

32 (24.1)

16 (10.1)

12 (7.6)

 Heart failure

2 (1.5)

3 (2.3)

20 (12.7)

13 (8.3)

Esaxerenone dose at baseline (initial dose), mg

 1.25

39 (28.5)

-

79 (50.0)

-

 2.5

98 (71.5)

-

79 (50.0)

-

Esaxerenone dose at EOT (last dose), mg

 1.25

19 (13.9)

-

46 (29.1)

-

 2.5

82 (59.9)

-

92 (58.2)

-

 5

36 (26.3)

-

20 (12.7)

-

Trichlormethiazide dose at baseline (initial dose), mg

 0.25

-

2 (1.5)

-

2 (1.3)

 0.5

-

10 (7.5)

-

7 (4.5)

 1

-

117 (88.0)

-

145 (92.4)

 2

-

4 (3.0)

-

3 (1.9)

Trichlormethiazide dose at EOT (last dose), mg

 0.25

-

2 (1.5)

-

0

 0.5

-

7 (5.3)

-

11 (7.0)

 1

-

109 (82.0)

-

135 (86.0)

 >1 to ≤2

-

13 (9.8)

-

11 (7.0)

 ≥3

-

2 (1.5)

-

0

Basal antihypertensive agent

 Angiotensin receptor blocker

56 (40.9)

56 (42.1)

63 (39.9)

60 (38.2)

 Calcium channel blocker

81 (59.1)

77 (57.9)

95 (60.1)

97 (61.8)

  1. Data are n (%) or mean ± standard deviation
  2. DBP diastolic blood pressure, eGFRcreat creatinine-based estimated glomerular filtration rate, EOT end of treatment, NT-proBNP N-terminal pro-brain natriuretic peptide, SBP systolic blood pressure, T2DM type 2 diabetes mellitus, UACR urinary albumin-to-creatinine ratio
Back to article page